Skip to main content
SpringerLink
Log in

Plasmafraktionierung und therapeutische Plasmaproteine

  • Chapter
Transfusionsmedizin und Immunhämatologie

  • 6784 Accesses

Zusammenfassung

Plasmaderivate sind gereinigte und in ihrer Konzentration standardisierte Proteine aus Plasma, dem zellfreien Bestandteil des menschlichen Blutes. Es gibt Menschen, denen diese Proteine aufgrund eines genetischen oder erworbenen Mangels in ausreichender Menge fehlen, was zu klinischen Symptomen bis hin zu lebensgefährlichen Erkrankungen führt. Solchen Patienten müssen diese Plasmaderivate infundiert werden. Die wichtigsten Proteine, die therapeutisch angewandt werden, sind in Tab. 19.1 zusammengestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Amareld RW Jr, Wersocki M, Drohan M, Drohan WN, Burgess WH, David M. Mann DM, et al. (2003) Controlled gamma-irradiation mediated pathogen inactivation of human urokinase preparations with significant recovery of enzymatic activity. Biologicals 31:261–264

    Article  PubMed  CAS  Google Scholar 

  2. Bauman PA, Lawrence LA, Biesert L, Dichtelmüller H, Fabbrizzi F, Gajardo R, et al. (2006) Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 91:34–40

    Article  PubMed  CAS  Google Scholar 

  3. Biescae H, Gensana M, Fernándes J, Ristol P, Massot M, Watson E, Vericat F (1998) Characterization and viral safety validation studies of a pasteurized therapeutic concentrated of antithrombin III obtained through affinity chromatography. Haematologica 83:305–311

    Google Scholar 

  4. Blümel J, Schmidt I, Willkommen H, Löwer J (2002) Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 42:1011–1018

    Article  PubMed  Google Scholar 

  5. Blümel J, Stühler A, Dichtelmüller H (2008) Kinetics of inactivating human parvovirus B19 and porcine parvovirus by dry-heat treatment. Transfusion 48:790–791

    Article  PubMed  Google Scholar 

  6. Boschetti N, Niederhauser I, Kempf C, Stühler A, Löwer J, Blümel J (2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44:1079–1086

    Article  PubMed  CAS  Google Scholar 

  7. Brown P, Rohwer RG, Gaidusek DC (1986) Newer data in the inactivation of scrapie virus or Creutzfeldt-Jakob disease virus in brain tissue. J Infect Dis 153:1145–1148

    Article  PubMed  CAS  Google Scholar 

  8. Burdick MD, Pifat DY, Petteway Jr. SR, Cai K (2006) Clearance of prions during plasma protein manufacture. Transfus Med Rev 20:57–62

    Article  PubMed  Google Scholar 

  9. Burdick MD, Pifat DY, Petteway Jr. SR, Cai K (2006) Clearance of prions during plasma protein manufacture. Transfus Med Rev 20:57–62

    Article  PubMed  Google Scholar 

  10. Burnouf T, Bournouf-Radosewich M, Huart JJ, Goudemand M (1991) A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 60:8–15

    Article  PubMed  CAS  Google Scholar 

  11. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T (1994) Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 67:132–138

    Article  PubMed  CAS  Google Scholar 

  12. Cai K, Miller JLC, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, et al. (2002) Solvent-dependent precipitation of prion protein. Biochim Biophys Acta 1597:28–35

    Article  PubMed  CAS  Google Scholar 

  13. Chang CE, Eo HG, Lee YS, Chang SK, Shin JS, Lah YK, et al. (2000) Human intravenous mmunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment. Prep Biochem Biotechnol 30:177–197

    Article  PubMed  CAS  Google Scholar 

  14. Chen SX, Hammond DJ, Klos AM, Wood WD, Wydick JE, Lebing WR (1998) Chromatographic purification of human α1 proteinase inhibitor from dissolved Cohn fraction IV-1 paste. J Chromatogr A 800:207–218

    Article  PubMed  CAS  Google Scholar 

  15. Chin S, Jin R, Wang X-L, Hamman J, Marx G, Mou X, et al. (1997) Virucidal treatment of blood protein products with UVC radiation. Photochem Photobiol 65:432–435

    Article  PubMed  CAS  Google Scholar 

  16. Chin S, Williams B, Gottlieb P, Margolis-Nunno H, Ben-Hur E, Hamman J, et al. (1995) Virucidal Short Wavelength Ultraviolet Light Treatment of Plasma and Factor VIII Concentrate: Protection of Proteins by Antioxidants. Blood 86:4331–4336

    PubMed  CAS  Google Scholar 

  17. Chtourou S, Porte P, Nogré M, Bihoreau N, Cheesman E, Samor B, et al. (2007) A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates. Vox Sang 92:327–337

    PubMed  CAS  Google Scholar 

  18. Cohn EJ, Strong LE, Hughes Jr. WL, Mulford DJ, Ashworth JN, Melin M, et al. (1946) Preparation and properties of serum and plasma proeins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Amer Chem Soc 68:459–475

    Article  CAS  Google Scholar 

  19. Cohn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Ashworth JN, Melin M, Taylor HL (1946) Preparation and properties of serum and plasma proteins. IV. A system for the separation into fraction of the protein and lipoprotein components of biological tissues and fluids. J Amer Chem Soc 68:459–475

    Article  CAS  Google Scholar 

  20. Corbin F 3rd (2002) Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol 76 (Suppl 2):253–257

    Article  PubMed  Google Scholar 

  21. Dichtelmüller H, Rudnick D, Breuer B, Gänshirt KH (1993) Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5 % serum protein solution treated with β-propiolactone. Bologicals 21:259–268

    Article  Google Scholar 

  22. Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Gröner A, von Hoegen I, et al. (2009) Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 49:1931–1943

    Article  PubMed  CAS  Google Scholar 

  23. Dike GWR, Bidwell E, Rizza CR (1972) The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and a separate concentrate containing factor VIII. Br J Haematol 22:469–490

    Article  PubMed  CAS  Google Scholar 

  24. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Elizabeth Higgins E, et al. (1998) Transgenically produced human antithrombin: Structural and functional comparison to human plasma– derived antithrombin. Blood 91:4561–4571

    PubMed  CAS  Google Scholar 

  25. EMEA (1996) Note for guidance on virus validation studies: The design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95

    Google Scholar 

  26. EMEA (1997) Note for Guidance on quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. CPMP/ICH/295/95

    Google Scholar 

  27. EMEA (2001) Note for Guidance on plasma-derived medicinal products. CPMP/BWP/269 Rev 3

    Google Scholar 

  28. EMEA (2004) CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. EMEA/CPMP/BWP/2879/02 Rev 1

    Google Scholar 

  29. EMEA (2004) Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. CPMP/BWP/CPMP/5136/03

    Google Scholar 

  30. EMEA (2009) Draft Guideline on plasma-derived mediccinal products. CPMP/BWP/269 Rev 4

    Google Scholar 

  31. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, et al. (2002) Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 42:190–197

    Article  PubMed  CAS  Google Scholar 

  32. Feldman F, Chandra S, Huang C (1995) Improved safety from plasma derivatives: Purifiction and viral elimination characteristics of Mononine. Acta Haematol 94 (Suppl 1):25–34

    Article  PubMed  Google Scholar 

  33. Fischer BE (1999) Recombinant von Willebrand Factor: Potential therapeutic use. J Thromb Thrombolysis 8:197–205

    Article  PubMed  CAS  Google Scholar 

  34. Flechsig E, Hegyi I, Enari M, Schwarz P, Collinge J, Weissmann C (2001) Transmission of scrapie by steel-surface-bound prions. Molecular Medicine 7:679–684

    PubMed  CAS  Google Scholar 

  35. Foster PR (1999) Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfusion Med 9:3–14

    Article  CAS  Google Scholar 

  36. Foster PR (2004) Removal of TSE agents from blood products. Vox Sang 87 (Suppl 2):S7–S10

    Article  CAS  Google Scholar 

  37. Fuhge P, Gratz P, Geiger H (1986) Moderne Methoden zur Herstellung von Gerinnungstherapeutika. Behring Inst Mitt 79:164–176

    CAS  Google Scholar 

  38. Furuya K, Murai K, Yokoyama T, Maeno H, Takeda Y, Murozuka T, et al. (2006) Implementation of a 20-nm pore-size filter in the plasmaderived Factor VIII manufacturing process. Vox Sang 91:119–125

    Article  PubMed  CAS  Google Scholar 

  39. Gareis-Helferich E, de Decker W, Groß G, Dokktor P, Geering H (1968) Bindehautwundverschluß durch fibrinöse Verklebung. Klin Monatsbl Augenheilk 153:74–77

    CAS  Google Scholar 

  40. Gellis SS, Neefe JR, Stokes J Jr, Strong LE, Janeway CA, Scatchard G (1948) Chemical, clinical, and immunological studies on the product of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 27:239–244

    Article  Google Scholar 

  41. Goldsmith JC (2000) Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates. Blood Coagulation Fibrinolysis 11:203–215

    PubMed  CAS  Google Scholar 

  42. Gregori L, Maring J-A, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG (2004) Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32:1–10

    Article  PubMed  CAS  Google Scholar 

  43. Grieb T, Forng R-Y, Brown R, Owolabi T, Maddox E, McBain A, et al. (2002) Effective use of gamma irradiation for pathogen inactivation of monoclonal antibody preparations. Biologicals 30:207–216

    Article  PubMed  CAS  Google Scholar 

  44. Groener A, Groschup M, Schäfer W (2008) Efficient Reduction of Prions by the Manufacturing Process of a VWF/FVIII Product. Blood 2008;112:995

    Google Scholar 

  45. Groener A, Nowak T, Schäfer W (2009) Parvovirus B19 Is Inactivated by Pasteurization, a Dedicated Virus Inactivation Step in the Manufacturing Process of Plasma-Derived Products. Blood (ASH Annual Meeting Abstracts) 114: Abstr 3152

    Google Scholar 

  46. Gröner A (2008) Pathogen safety of plasma-derived products – Haemate ® P/Humate-P®. Haemophilia 14 (Suppl 5): 54–71

    Article  PubMed  Google Scholar 

  47. Hammarsten O (1879) Ueber das Fibrinogen. In: E Pflüger (Hrsg) Archiv f. Physiologie 19:563–622

    Google Scholar 

  48. Hart H, Reid K, Hart W (1993) Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin. Vox Sang 64:82–88

    Article  PubMed  CAS  Google Scholar 

  49. Haupt H, Heimburger N, Kranz T Schwick HG (1970) Ein Beitrag zur Isolierung und Charakterisierung des C1-Inaktivators aus Humanplasma. Eur J Biochem 17:254–261

    Article  PubMed  CAS  Google Scholar 

  50. Heimburger N, Schwinn H, Gratz P, Lüben G, Kumpe G, Herchenhan B (1981) FVIII-Konzentrat, hochgereinigt und in Lösung erhitzt. Arzneimittelforschung 31:619–622

    PubMed  CAS  Google Scholar 

  51. Heimburger N, Schwinn H, Graz P, Lüben G, Kumpe G, Herchhan B (1981) FaktorVIII-Konzentrat, hochgereinigt und in Lösung erhitzt. Arzneimittelforschung 31:619–622

    PubMed  CAS  Google Scholar 

  52. Hein RH, van Beveren SM, Shearer MA, Coan MH, Brockway WJ (1990) Production of α1-proteinase inhibitor (human). Europ Respir J 3 (Suppl 9): 16–20

    Google Scholar 

  53. Hilfenhaus J, Weidmann E (1986) Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates. Arzneim-Forsch/Drug Res 36:621–625

    CAS  Google Scholar 

  54. Hoffer L, Schwinn H, Biesert L, Josic DJ (1995) Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration. J Chromatogr B 669:187–196

    Article  CAS  Google Scholar 

  55. Horowitz B, Wiebe ME, Lippin A, Stryker MH (1985) Inactivation of viruses in labile blood derivatives. I. Disruption of lipid enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 25:516–522

    Article  PubMed  CAS  Google Scholar 

  56. Horowitz B, Prince AM, Horowitz MS, Watklevicz C (1993) Viral safety of solvent-detergent treated blood products. Dev Biol Stand 81:147–161

    PubMed  CAS  Google Scholar 

  57. Hrinda ME, Feldman F, Schreiber AB (1990) Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIII. Semin Hematol 27 (Suppl 2):19–24

    PubMed  CAS  Google Scholar 

  58. Johnson AJ, MacDonald VE, Bird J (1979) Enhanced yield of antihemophilic factor and von Willebrand factor by cryoprecipitation with polyethylene glycol. Vox Sang 36:72–76

    Article  PubMed  CAS  Google Scholar 

  59. Johnston A, Adcock W (2000) The use of chromatography to manufacture purer and safer plasma products. Biotech Gen Engineer Rev 17:37–70

    CAS  Google Scholar 

  60. Josić D, Hoffer L, Buchacher A, Schwinn H, Frenzel W, Biesert L, et al. (2000) Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thrombosis Res 100:433–441

    Article  Google Scholar 

  61. Karges HE, Clemens R (1988) Factor XIII: Enzymatic and clinical aspects. Behring Inst Mitt 82:43–58

    PubMed  CAS  Google Scholar 

  62. Karges HE, Fuhge P, Heimburger N (1987) Eigenschaften und Virussicherheit eines pasteurisierten Antithrombin III-Konzentrates. Drug Res 37:756–758

    CAS  Google Scholar 

  63. Käsermann F, Kempf C (2003) Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol 84:3173–3176

    Article  PubMed  CAS  Google Scholar 

  64. Käsermann F, Wyss K, Kempf C (2001) Virus inactivation and protein modifications by ethyleneimines. Antiviral Res 52:33–41

    Article  PubMed  Google Scholar 

  65. Kempf C, Jentsch P, Poirier B, Barré-Sinoussi F, Morgenthaler JJ, Morell A, et al. (1991) Virus inactivation during production of intravenous immunoglobulin. Transfusion 31:423–427

    Article  PubMed  CAS  Google Scholar 

  66. Kistler P, Nitschman H (1962) Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation of Nitschman, Kistler, and Lergier. Vox Sang 7:414–424

    Article  PubMed  CAS  Google Scholar 

  67. Kobayashi K (2006) Summary of recombinant human serum albumin development. Biologicals 34:55–59

    Article  PubMed  CAS  Google Scholar 

  68. Kobayashi K, Kuwae S, Ohya T, Ohda T, Ohyama M, Ohi H, et al. (2000) High-Level Expression of Recombinant Human Serum Albumin from the Methylotrophic Yeast Pichia pastoris with Minimal Protease Production and Activation. J Biosci Bioengineer 89:55–61

    Article  CAS  Google Scholar 

  69. Kreil TR, Breiting A, Kristner O, Kindermann J (2003) West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 43:1023–1028

    Article  PubMed  Google Scholar 

  70. Kreil TR, Wieser A, Berting A, Spruth M, Medek C, Pölsler G, et al. (2006) Removal of small non-enveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives Transfusion 46:1143–1151

    Google Scholar 

  71. Kurachi K, Davie EW (1982) Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci 79:6461–6464

    Article  PubMed  CAS  Google Scholar 

  72. Lebing W, Remington KM, Schreiner C, Paul H-I (2003) Properties of a new intravenous immunoglobulin (IVIG-C, 10 %) produced by virus inactivation with caprylate and column chromatography. Vox Sang 84:193–201

    Article  PubMed  CAS  Google Scholar 

  73. Lebing WR, Hammond DJ, Wydick III JE, Baumbach GA (1994) A highly purified antithrombin III cioncetrate prepared from human plasma fraction IV-1 by affinity chromatography. Vox Sang 67:117–124

    Article  PubMed  CAS  Google Scholar 

  74. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murphy KK, et al. (2005) Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 45:580–590

    Article  PubMed  CAS  Google Scholar 

  75. Lorenz CM, Wolk BM, Quan CP, Alcala EW, Eng M, McDonald DJ, et al. (2009) The Effect of Low Intensity Ultraviolet-C Light on Monoclonal Antibodies. Biotechnol Prog 25:476–482

    Article  PubMed  CAS  Google Scholar 

  76. Marx G, Mou X, Freed R, Ben-Hur E, Yang C, Horowitz B (1996) Protecting fibrinogen with rutin during UVC irradiation for viral inactivation. Photochem Photobiol 63:541–546

    Article  PubMed  CAS  Google Scholar 

  77. Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S (2004) In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 86:100–104

    Article  PubMed  CAS  Google Scholar 

  78. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 102: 634–644

    PubMed  CAS  Google Scholar 

  79. Miekka SI, Forng R-Y, Rohwer RG, MacAuley C, Stafford RE, Flack SL, et al. (2003) Inactivation of viral and prion pathogens by γ-irradiation under conditions that maintain the integrity of human albumin. Vox Sang 84:36–44

    Article  PubMed  CAS  Google Scholar 

  80. Miller-Andersson M, Borg H, Andersson LO (1974) Purification of antithrombin III by affinity chromatography. Thromb Res 5:439–452

    Article  CAS  Google Scholar 

  81. Mohr H, Bachmann B, Klein-Struckmeier A, Lambrecht B (1997) Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol 65:441–445

    Article  PubMed  CAS  Google Scholar 

  82. Mori F, Nardini I, Rossi P, Nardini C, Farina C (2008) Progress in largescale purification of factor VIII/von Willebrand factor concentrates using ion-exchange chromatography. Vox Sanguinis 95:298–307

    Article  PubMed  CAS  Google Scholar 

  83. Morrica A, Nardini C, Falbo A, Bailey AC, Bucci E (2003) Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance. Biologicals 31:165–173

    Article  PubMed  CAS  Google Scholar 

  84. Neurath AR, Vernon SK, Dobkin MB, Rubin BA (1972) Characterization of subviral components resulting from treatment of rabies virus with tri(n-butyl) phosphate. J Gen Virol 14:33–48

    Article  PubMed  CAS  Google Scholar 

  85. Nowak T, Gregersen J-P, Klockmann U, Cummins LB, Hilfenhaus J (1992) Virus safety of human immunoglobulins: Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol 36:209–216

    Article  PubMed  CAS  Google Scholar 

  86. Nowak T, Niedrig M, Bernhardt D, Hilfenhaus J (1993) Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation. Dev Biol Stand 81:169–176

    PubMed  CAS  Google Scholar 

  87. Omar A, Kempf C (2002) Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion 42:1005–1010

    Article  PubMed  CAS  Google Scholar 

  88. Oncley JL, Melin M (1949) The separations of antibodies, isoagglutinins, prothrombin, plasminogen, and beta-1-lipoprotein in subfractions of human plasma. J Am Chem Soc 71:541–550

    Article  PubMed  CAS  Google Scholar 

  89. Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, et al. (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 115:2057–2064

    Article  PubMed  CAS  Google Scholar 

  90. Pipe SW (2008) Recombinant clotting factors. Thromb Haemost 99:840–850

    PubMed  CAS  Google Scholar 

  91. Plaimauer B, Schlokat U, Turecek PL, Mitterer A, Mundt W, Auer W, Pichler L, Gritsch H, Dorner F, Schwarz H-P (2001) Recombinant von Willebrand Factor: Preclinical development. Semin Thromb Hemost 27:395–403

    Article  PubMed  CAS  Google Scholar 

  92. Purmal A, Valeri CR, Dzik W, Pivacek L, Ragno G, Lazo A, et al. (2002) Process of the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 42:139–145

    Article  PubMed  Google Scholar 

  93. Quirk AV, Geisow MJ, Woodrow JR, Burton SJ, Wood PC, Sutton AD, et al. (1989) Production of recombinant human serum albumin from Saccharomyces cerevisiae. Biotechnol Appl Biochem 11:273–287

    PubMed  CAS  Google Scholar 

  94. Radosevich M, Burnouf T (2010) Intravenous immunogloulin G: trends in production methods, quality control and quality assurance. Vox Sang 98:17–28

    Article  CAS  Google Scholar 

  95. Raut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe TW, Laub R (1998) Modification of Factor VIII in Therapeutic Concentrates after Virus Inactivation by Solvent-Detergent and Pasteurisation. Thromb Haemost 80: 624–631

    PubMed  CAS  Google Scholar 

  96. Reid KG, Cuthbertson B, Jones ADL, McIntosh RV (1988) Potential contribution of mild pepsin treatment at pH 4 to the viral safety of human immunoglobulin products. Vox Sang 55:75–80

    Article  PubMed  CAS  Google Scholar 

  97. Roberts PL, Dunkerley C, McAuley A, Winkelman L (2007) Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 °C in factor VIII. Vox Sang 92:56–63

    Article  PubMed  CAS  Google Scholar 

  98. Robertson JS, Blümel J, Kurt Brorson K, Gröner A, Kreil TR, Ruiz S, Willkommen H (2009) Meeting report Virus & TSE safety forum 2008. Biologicals 37:345–354

    Article  PubMed  Google Scholar 

  99. Römisch J, List W, Bernhardt D, Diehl K-H, Gröner A, Hein B, et al. (1995) Nanofiltration bei der Herstellung des PPSB-Präparates Beriplex® P/N. Haemostaseologie 15:171–178

    Google Scholar 

  100. Römisch J, Gröner A, Bernhardt D, Diehl KH, Hein B, List W, et al. (1996) Nanofiltration bei der Herstellung von Beriplex®P/N: Erhöhung der Kapazität zur Viruseliminierung unter Beibehaltung der Produktqualität. Beitr Infusionsther Transfusionsmed 33:220–224

    PubMed  Google Scholar 

  101. Savage M, Torres J, Franks L, Masecar B, Hotta J (1998) Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and by near infrared spectroscopy. Biologicals 26:119–124

    Article  PubMed  CAS  Google Scholar 

  102. Saywer WA, Meyer KF, Eaton MD, Bauer JH, Putnam P, Schwentker FF (1944) Jaundice in the army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am J Hyg 39: 337–430

    Google Scholar 

  103. Schimpf K, Mannucci PM, Kreutz W, Brackmann HH, Auerswald G, Clavarella N, et al. (1987) Absence of hepatitis after treatment with pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. N Engl J Med 316:918–922

    Article  PubMed  CAS  Google Scholar 

  104. Schimpf K, Brackmann HH, Kreutz W, Kraus B, Haschke F, Schramm W, et al. (1989) Absence of anti-human immunodeficiency virus type 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand’s disease with pasteurized factor VIII concentrate. N Engl J Med 321:1148–1152

    Article  PubMed  CAS  Google Scholar 

  105. Schmidt S, Kauling J (2006) UV-Inaktivierung von Viren und Bakterien mit einem innovativen Wendelrohrreaktor im Labor- und Prozessmaßstab. Chemie Ingenieur Technik 76:1739–1745

    Article  CAS  Google Scholar 

  106. Stucki M, Moudry R, Kempf C, Omar A, Schlegel A, Lerch PG (1997) Characterisation of a chromatogrphically produced anti-D immunoglobulin product. J Chromatogr B 700:241–248

    Article  CAS  Google Scholar 

  107. Stucki M, Boschetti N, Schäfer W, Hostettle T, Käsermann F, Nowak T, Gröner A, Kempf C (2008) Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 36:239–247

    Article  PubMed  CAS  Google Scholar 

  108. Surgenor DM (2001) Edwin J. Cohn and the development of protein chemistry. Harvard University Press, Boston MA

    Google Scholar 

  109. Terpstra FG, Parkkinen J, Tölö H, Koenderman AHL, ter Hart HGJ, von Bonsdorff L, et al. (2006) Viral safety of Nanogam→, a new 15 nm-filtered liquidimmunoglobulin product. Vox Sang 90:21–32

    Article  PubMed  CAS  Google Scholar 

  110. Terpstra FG, Kleijn M, Koenderman AHL, Over J, van Engelenburg FAC, Schuitemaker H, van’t Wout AB (2007) Viral safety of C1-inhibitor NF. Biologicals 35:173–181

    Article  PubMed  CAS  Google Scholar 

  111. Teschner W, Butterweck HA, Auer W, Muchitsch E-M, Weber A, Liu S-L, Wah P-S, Schwarz H-P (2007) A new liquid, intravenous immunoglobulin product (IGIV 10 %) highly purified by a state-of-the-art process. Vox Sang 92:42–55

    Article  PubMed  CAS  Google Scholar 

  112. Thyer J, Unal A, Hartel G, Middleton D, Bingham J, Braun M, et al. (2006) Investigation of prion removal/inactivation from chromatographic gel. Vox Sang 91:301–308

    Article  PubMed  CAS  Google Scholar 

  113. Vey M, Baron H, Weimer T, Gröner A (2002) Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 30:187–196

    Article  PubMed  CAS  Google Scholar 

  114. Wang J, Mauser A, Chao S-F, Remington K, Treckmann R, Kaiser K, et al. (2004) Virus inactivation and protein recovery in a novel ultravialet-C reactor. Vox Sang 86:230–238

    Article  PubMed  CAS  Google Scholar 

  115. Wickerhausen M, Williams C, Mercer J (1979) Development of large scale fractionation methods: Preparation of antithrombin III concetrates. Vox Sang 36:281–293

    Article  Google Scholar 

  116. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, et al. (1984) Expression of active human factor VIII from recombinant DNA clones. Nature 312:330–337

    Article  PubMed  CAS  Google Scholar 

  117. Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N, Tomono T (2004) Removal of small non-enveloped viruses by nanofiltration. Vox Sang 86:225–229

    Article  PubMed  CAS  Google Scholar 

  118. Zimmerman TS (1988) Purification of factor VIII by monoclonal antibody afinity chromatography. Semin Haematol 25 (Suppl 1):25–26

    CAS  Google Scholar 

  119. Zimmerman TP (2006) Yield improvement for manufacture of α1 proteinase inhibitor. Vox Sang 91:309–315

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CSL Behring GmbH, Emil-von-Behring-Str. 76, 35041, Marburg

    Dr. A. Gröner

  2. Hermann-Bahner-Straße 15, 63225, Langen

    Dipl. HTL-Ing. M. Konrad

Authors
  1. Dr. A. Gröner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dipl. HTL-Ing. M. Konrad
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Transfusionsmedizin, Universitätsklinikum Rostock AöR, Ernst-Heydemann-Str. 6, 18057, Rostock

    Volker Kiefel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gröner, A., Konrad, M. (2010). Plasmafraktionierung und therapeutische Plasmaproteine. In: Kiefel, V., Mueller-Eckhardt, C. (eds) Transfusionsmedizin und Immunhämatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12765-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12765-6_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12764-9

  • Online ISBN: 978-3-642-12765-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation